Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Selects Cancer Target under Regulus Partnership


Regulus Therapeutics this week announced that AstraZeneca has selected an undisclosed oncology target under the companies' ongoing partnership to develop microRNA-targeting drugs for oncology and cardiovascular and metabolic diseases.

The companies began working together last year, agreeing to co-develop and –commercialize miRNA drugs against three exclusive targets, including potentially miRNA-33 in atherosclerosis (GSN 8/16/2012).

Regulus received $28 million upfront, which included an equity investment, and stands to be paid milestones and royalties.